Telix Pharmaceuticals Limited has announced that it has selected Cardinal Health, Inc. as one of its commercial distributors for Gozellix (kit for the preparation of gallium-68 (68Ga) gozetotide injection), a next-generation PSMA-PET imaging agent for prostate cancer, following recent US Food and Drug Administration (FDA) approval.

According to the company, this partnership aims to ensure wide availability of Gozellix across a broad range of US locations in preparation for the agent’s commercial launch in the first half of 2025.

To facilitate this, Cardinal Health has deployed Telix’s ARTMS QUANTM Irradiation System (QIS) cyclotron technology, which supports the efficient and cost-effective production of cyclotron-produced gallium-68 for use with Gozellix. This technology is designed to enable multi-Curie local production of gallium-68, further enhancing the distribution process.

Kevin Richardson, chief executive officer of Telix Precision Medicine, said: “Cardinal Health’s broad geographic reach and service excellence have been essential to the commercial success of Illuccix. The company believes that expanding this relationship will bring the clinical benefits of gallium-based imaging to even more patients across the U.S. with Gozellix.”

Mike Pintek, president of Cardinal Health Nuclear & Precision Health Solutions, added: “We are pleased to continue our relationship with Telix, which now includes the distribution of Illuccix, Zircaix and Gozellix. The combination of our established commercial distribution network and the innovative ARTMS production technology will enable us to extend patient reach and offer greater flexibility for gallium-based PSMA imaging.”

Cardinal Health will work alongside Telix’s in-house radiopharmacy network to distribute Gozellix.